St. Jude Medical Announces Data to be Presented as Late-Breaking Clinical Trials & Highlights Its Latest Cardiovascular Portf...
October 24 2016 - 8:00AM
Business Wire
Data presentations and multiple product releases demonstrate the
company’s commitment to transforming the treatment of
cardiovascular disease
St. Jude Medical, Inc. (NYSE:STJ), a global medical device
company, announced today that it will have new data featured during
late-breaking clinical trial presentations at the upcoming 2016
Transcatheter Cardiovascular Therapeutics educational meeting in
Washington, D.C., October 29 – November 2. Throughout the congress,
the company will also feature its latest cardiovascular
innovations, including PressureWire™ X guidewire, the latest
generation of the pioneering PressureWire guidewire system;
structural heart solutions and the CardioMEMS™ HF System.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20161024005224/en/
St. Jude Medical will have new data
featured during late-breaking clinical trial presentations at the
upcoming 2016 Transcatheter Cardiovascular Therapeutics symposium.
Throughout the congress, the company will also feature its latest
cardiovascular innovations that demonstrate its commitment to
transforming the treatment of cardiovascular disease. (Photo:
Business Wire)
Three late-breaking or first report investigation sessions and
one oral abstract presentation will highlight data from St. Jude
Medical advancements in vascular and structural heart
technologies.
- A comparison of stent visualization
technologies for use during percutaneous coronary intervention
(PCI) – Data from the first randomized clinical trial to compare
OCT-guided, IVUS-guided and angiography-guided PCI
The session: “ILUMIEN III (OPTIMIZE PCI): A
Prospective, Randomized Trial of OCT-Guided vs. IVUS-Guided vs.
Angio-Guided Stent Implantation in Patients with Coronary Artery
Disease,” will be presented by Dr. Ziad A. Ali, associate director
of translational medicine at the Center for Interventional Vascular
Therapy at Columbia University Medical Center in New York at 9 a.m.
on Sunday, October 30. This is the first late-breaking clinical
trial presentation of TCT 2016.
- Final long term results from the
RESPECT trial, comparing recurrent stroke in patients with the
AMPLATZER™ PFO closure device to contemporary medical
management
The session: “RESPECT: Final Long-Term
Outcomes from a Prospective, Randomized Trial of PFO Closure in
Patients with Cryptogenic Stroke,” will be presented by Dr. David
Thaler, neurologist-in-chief at Tufts Medical Center and chairman
of the Department of Neurology at Tufts University School of
Medicine in Boston, at 12:15 p.m. on Tuesday, November 1.
Previous results observed a stroke reduction
across the totality of analyses with rates ranging from 51-73
percent.
- Initial data from the largest,
prospective evaluation of the AMPLATZER™ Amulet™ LAA occluder
device, designed to seal the left atrial appendage to prevent
stroke in patients with non-valvular atrial fibrillation
The session: “AMULET OBSERVATIONAL STUDY:
Multicenter, Prospective, Registry Results with a Left Atrial
Appendage Closure Device for Stroke Prevention in Patients with
Atrial Fibrillation,” will be presented by Dr. David Hildick-Smith,
cardiologist at Brighton & Sussex University Hospitals in the
UK, at 9:40 a.m. on Wednesday, November 2.
Leading interventional cardiologists will also be on hand to
demonstrate the OPTIS™ integrated system from 10-11 a.m. and from
2-3 p.m. each day during exhibit hours (Sunday, Oct. 30, Monday,
October 31 and Tuesday, November 1).
Additionally, on Sunday, October 31, St. Jude Medical is
sponsoring a TCT satellite symposium, "Interventional management of
complex patients, cutting edge technologies for the advanced
interventionalist.” For more information about this event, visit:
http://www.crf.org/tct/agenda/satellite-programs.
About St. Jude Medical
St. Jude Medical is a leading global medical device manufacturer
and is dedicated to transforming the treatment of some of the
world’s most expensive epidemic diseases. The company does this by
developing cost-effective medical technologies that save and
improve lives of patients around the world. Headquartered in St.
Paul, Minn., St. Jude Medical has five major areas of focus that
include heart failure, atrial fibrillation, neuromodulation,
traditional cardiac rhythm management, and cardiovascular. For more
information, please visit sjm.com or follow us on Twitter
@SJM_Media.
Forward-Looking Statements
This news release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995
that involve risks and uncertainties. Such forward-looking
statements include the expectations, plans and prospects for the
company, including potential clinical successes, reimbursement
strategies, anticipated regulatory approvals and future product
launches, and projected revenues, margins, earnings and market
shares. The statements made by the company are based upon
management’s current expectations and are subject to certain risks
and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements.
These risks and uncertainties include market conditions and other
factors beyond the company’s control and the risk factors and other
cautionary statements described in the company’s filings with the
SEC, including those described in the Risk Factors and Cautionary
Statements sections of the company’s Annual Report on Form 10-K for
the fiscal year ended January 2, 2016 and Quarterly Report on Form
10-Q for the fiscal quarter ended July 2, 2016. The company does
not intend to update these statements and undertakes no duty to any
person to provide any such update under any circumstance.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161024005224/en/
St. Jude Medical, Inc.J.C. Weigelt, 651-756-4347Investor
Relationsjweigelt@sjm.comorGina O’Connell, 651-756-3380Media
RelationsGoconnell02@sjm.com
SJM (NYSE:STJ)
Historical Stock Chart
From Aug 2024 to Sep 2024
SJM (NYSE:STJ)
Historical Stock Chart
From Sep 2023 to Sep 2024